IDEXX Laboratories, Inc. vs Norwegian Cruise Line Holdings Ltd — how do they compare? IDEXX Laboratories, Inc. trades at $588.5 (market cap $46.22B), while Norwegian Cruise Line Holdings Ltd trades at $18.81 (market cap $8.59B). The key difference: IDEXX Laboratories, Inc. is far larger — about 5.4× Norwegian Cruise Line Holdings Ltd's market cap. Which is the better fit depends on your goals.
| IDXX | NCLH | |
|---|---|---|
Market Cap | $46.22B | $8.59B |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $26.94 |
52-Week Low | $526.44 | $14.79 |
Enterprise Value | $47.12B | $23.40B |
Trailing returns across standard periods
Latest headlines on both assets
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →